TRUMENBA safety information
Scroll for Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION
- Severe allergic reaction after a previous dose of Trumenba is a contraindication
- Individuals with altered immunocompetence may have reduced immune responses to Trumenba
- In clinical studies, the most common solicited adverse reactions were pain at the injection site (≥85%), fatigue (≥40%), headache (≥35%), muscle pain (≥30%), and chills (≥15%)
- Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
- Safety and effectiveness has not been established in pregnant women
- Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
- Approval of Trumenba is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of Trumenba against diverse serogroup B strains has not been confirmed
Please see full Prescribing Information.
Vaccinate with TRUMENBA
A collection of services designed to help you and your practice protect against MenB in adolescent and young adult patients 10 through 25 years of age.
Trumenba Home page video block
Only TRUMENBA targets both subfamilies, A and B, of factor H binding protein (fHBP).1
TRUMENBA in your practice
Why adolescents and young adults?
TRUMENBA clinical studies
*Advisory Committee on Immunization Practices.
- Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2016.
- MacNeil JR, Rubin L, Folaranmi T, et al. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR. 2015;64(41):1171-1177.
- Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. http://www.cdc.gov/meningococcal/index.html. Updated March 4, 2016. Accessed May 5, 2016.